Over the past 12 months, Kiniksa Pharmaceuticals International insiders sold $60.29 million of stock on the open market (1.3Mn shares) and made no open-market purchases.
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Bros. Advisors Lp Baker | Director | 0 | 5,470,583 | 5,470,583 | 80.6% | 02 Jun, 2026 |
| 2 | Sanj K Patel | Chairman Ceo | 63,012 | 718,508 | 781,520 | 11.5% | 03 Sep, 2026 |
| 3 | Eben Tessari | Chief Strategy Officer | 149,154 | 0 | 149,154 | 2.2% | 08 Apr, 2026 |
| 4 | John F. Paolini | Chief Medical Officer | 117,725 | 0 | 117,725 | 1.7% | 03 Sep, 2026 |
| 5 | Michael R Megna | Chief Accounting Officer | 50,390 | 0 | 50,390 | 0.7% | 03 Sep, 2026 |
| 6 | Mark Ragosa | Chief Financial Officer | 40,107 | 0 | 40,107 | 0.6% | 03 Sep, 2026 |
| 7 | Richard S Levy | Director | 35,256 | 0 | 35,256 | 0.5% | 04 Aug, 2026 |
| 8 | Ross Moat | Chief Operating Officer | 32,583 | 0 | 32,583 | 0.5% | 03 Sep, 2026 |
| 9 | Kimberly J Popovits | Director | 24,718 | 0 | 24,718 | 0.4% | 02 Jun, 2026 |
| 10 | Thomas Malley | Director | 24,718 | 0 | 24,718 | 0.4% | 02 Jun, 2026 |
| 11 | Tracey L Mccain | Director | 24,718 | 0 | 24,718 | 0.4% | 02 Jun, 2026 |
| 12 | Barry D Quart | Director | 22,118 | 0 | 22,118 | 0.3% | 21 Aug, 2026 |
| 13 | G Bradley Cole | Director | 16,545 | 0 | 16,545 | 0.2% | 31 Jul, 2026 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 01 Sep, 2026 | Sanj K Patel | Chairman Ceo | Acquired M | 9,991 | — | — | 86,165 | Indirect |
| 01 Sep, 2026 | Ross Moat | Chief Operating Officer | Acquired M | 2,477 | — | — | 14,506 | Direct |
| 01 Sep, 2026 | Sanj K Patel | Chairman Ceo | Acquired M | 9,991 | — | — | 86,165 | Indirect |
| 01 Sep, 2026 | Mark Ragosa | Chief Financial Officer | Acquired M | 2,694 | — | — | 18,848 | Direct |
| 01 Sep, 2026 | John F. Paolini | Chief Medical Officer | Acquired M | 2,497 | — | — | 68,120 | Direct |
| 15 Jul, 2026 | Michael R Megna | Chief Accounting Officer | Acquired A | 279 | $33.50 | $9.35K | 27,697 | Direct |
| 01 Sep, 2026 | Mark Ragosa | Chief Financial Officer | Acquired M | 1,750 | — | — | 20,598 | Direct |
| 01 Sep, 2026 | Ross Moat | Chief Operating Officer | Acquired M | 1,611 | — | — | 16,117 | Direct |
| 01 Sep, 2026 | Sanj K Patel | Chairman Ceo | Acquired M | 6,481 | — | — | 92,646 | Indirect |
| 01 Sep, 2026 | John F. Paolini | Chief Medical Officer | Acquired M | 1,624 | — | — | 69,744 | Direct |
| 01 Sep, 2026 | Michael R Megna | Chief Accounting Officer | Acquired M | 3,932 | — | — | 31,629 | Direct |
| 01 Sep, 2026 | Sanj K Patel | Chairman Ceo | Acquired M | 6,481 | — | — | 92,646 | Indirect |
| 01 Sep, 2026 | John F. Paolini | Chief Medical Officer | Acquired M | 1,750 | — | — | 71,494 | Direct |
| 01 Sep, 2026 | Ross Moat | Chief Operating Officer | Acquired M | 1,740 | — | — | 17,857 | Direct |
| 01 Sep, 2026 | Sanj K Patel | Chairman Ceo | Acquired M | 6,237 | — | — | 98,883 | Indirect |
| 01 Sep, 2026 | Mark Ragosa | Chief Financial Officer | Acquired M | 1,591 | — | — | 22,189 | Direct |
| 01 Sep, 2026 | Michael R Megna | Chief Accounting Officer | Acquired M | 2,558 | — | — | 34,187 | Direct |
| 01 Sep, 2026 | Sanj K Patel | Chairman Ceo | Acquired M | 6,237 | — | — | 98,883 | Indirect |
| 01 Sep, 2026 | Sanj K Patel | Chairman Ceo | Acquired M | 8,609 | — | — | 107,492 | Indirect |
| 01 Sep, 2026 | Sanj K Patel | Chairman Ceo | Acquired M | 8,609 | — | — | 107,492 | Indirect |